Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx, Inc. (CDNA) announced the successful completion of CLIA validation for AlloMap Kidney, a blood-based gene expression classifier identifying immune quiescence, crucial for assessing rejection risk and allograft health. The clinical validation indicates AlloMap Kidney can differentiate between rejection types and immune quiescence, achieving a combined area under the curve (AUC) of 0.894. This validation is a significant step toward commercializing the KidneyCare multimodality solution, enhancing monitoring for kidney transplant health.
CareDx Acquires The Transplant Pharmacy to Enhance Support for Organ Transplant Patients. Located in Flowood, Mississippi, The Transplant Pharmacy specializes in individualized medication management services for transplant patients across the U.S. This acquisition strengthens CareDx’s connection with patients and expands its portfolio, which includes AlloCare™, Transplant Hero™, and MedActionPlan. CEO Reg Seeto emphasized the importance of medication adherence in improving patient outcomes. The acquisition aims to deliver personalized pharmaceutical care, ultimately benefiting organ transplant recipients.
CareDx, Inc. (Nasdaq: CDNA) has partnered with the International Society for Heart and Lung Transplantation (ISHLT) to introduce the Innovation Challenge Award. This initiative aims to promote research on the clinical utility of donor-derived cell-free DNA (dd-cfDNA) and gene expression profiling (GEP) methodologies in heart and lung transplants. Applications are open until January 31, 2022, with finalists presenting at the ISHLT 2022 Annual Meeting in April. Dr. Sham Dholakia expressed the importance of these non-invasive techniques for improving long-term transplant patient outcomes.
CareDx, Inc. has initiated the ALAMO registry, enrolling 1,000 lung transplant patients across the U.S. to enhance clinical decision-making. This study aims to evaluate LungCare's capability to detect transplant infections and rejections. Utilizing tests like AlloSure, AlloMap, and AlloID, the registry will track outcomes over three years, focusing on survival rates and severe infections. The development of multimodality diagnostics is expected to provide significant benefits in managing lung transplant recipients, potentially reducing the need for invasive biopsies.
CareDx, Inc. has partnered with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) to utilize their pediatric patient registry for a long-term outcomes study of AlloSure, a donor-derived cell-free DNA service aimed at improving organ transplant care in pediatric kidney patients. The study will track data for five years or until its conclusion, validating the utility of dd-cfDNA testing in managing long-term patient outcomes. This collaboration highlights CareDx's commitment to providing innovative solutions for pediatric transplant patients.
CareDx announced that over 80,000 organ transplant patients have utilized its AlloSure and AlloMap tests for post-transplant care. These tests are widely used, with over 90% of heart transplant centers and 70% of kidney transplant centers employing AlloSure and AlloMap. The recent launch of AlloSure Lung has also seen adoption in over 20 centers. CEO Reg Seeto emphasized the importance of active monitoring for transplant recipients, highlighting patient testimonials that illustrate the tests' positive impact on patient care.
Summary not available.
CareDx (Nasdaq: CDNA) has initiated the TEAMMATE study, the largest digital study to assess the AlloCare app's impact on organ transplant patients. Enrolling 4,000 participants from over 100 transplant centers, the study will analyze 90-day readmission rates and other health metrics across various organ transplants. The AlloCare app aids in medication management and tracking vital signs, aiming to improve patient adherence and outcomes. The study is crucial for evaluating whether technology can enhance transplant care.
CareDx, a precision medicine company focused on transplant patients, announced its participation in the 12th Annual Jefferies London Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference. The management team will present at these events, with a pre-recorded fireside chat available starting November 18, 2021, at 8:00 AM GMT, and a live chat on December 1, 2021, at 2:15 PM EST. Interested investors can listen to the webcasts via the company’s investor relations website.
CareDx has announced its acquisition of MedActionPlan, enhancing its technology suite aimed at improving medication adherence for transplant patients. MedActionPlan's platforms, including MedActionPlan PRO and MyMedSchedule Plus, are utilized in over 100 healthcare systems. This strategic integration aligns with CareDx's mission to enhance patient outcomes through better medication management post-transplant. The acquisition is expected to amplify CareDx's reach and strengthen its offerings in the transplant medication management space.